InSilico Medicine, the company focused on drug discovery for cancer and
age-related diseases, announced its investment in a research
collaboration with Canada Cancer and Aging Research Laboratories, Inc
(CCARL). The companies will collaborate on improving decision making in
clinical oncology and discovery, and personalized medicine projects in
multiple sclerosis (MS).
The mechanisms and causes of multiple sclerosis (MS), an inflammatory
disease on nerve cells, are not fully understood. MS commonly reveals
itself between ages of 20 and 50, and results in significant decrease in
life expectancy and loss of productivity. This partnership aims to
advance knowledge and science dedicated to this disease and more.
"To my knowledge CCARL is the first company in Canada to engage into
personalized medicine in clinical oncology with the aim to better
understand the underlying age-related pathologic processes and use that
knowledge for geroprotectors discovery", said Evgeny Makariev, director
of aging research at Insilico Medicine, Inc.
"Dr. Olga Kovalchuk was included into Canada's 40 under 40 and 25 most
influential women in the Canadian market for a very good reason. We were
very impressed by the level of enthusiasm, expertise and quality of
scientific research in genetics and epigenetics in her lab at the
University of Lethbridge. CCARL has many innovative ideas on how to
apply aging research to drug discovery and personalized medicine and
accelerate human trials. They came up with a very clever trick on how to
extrapolate some of the personalized medicine in oncology to multiple
sclerosis. Their world-class team brings decades of experience in
epigenetics, metagenomics and proteomics and approaching aging from a
completely new angle which may result in practical applications within
the next several years. Solving aging will require a concerted global
effort and we would like to partner with one of the top research teams
in Canada", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine, Inc.
No comments:
Post a Comment